Correction to: Drugs & Therapy Perspectives https://doi.org/10.1007/s40267-018-0531-1
Page 294, column 1, first sentence: the following text, which previously read:
“In a secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION, mortality rates did not differ to a significant extent between the ambrisentan + tadalafil and pooled monotherapy groups at the end of the 24-week trial (10 vs 14% of patients; HR 0.67; 95% CI 0.42–1.08; log-rank p = 0.10) [24]”.
Should read:
“In a secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION, mortality rates did not differ to a significant extent between the ambrisentan + tadalafil and pooled monotherapy groups at the end of the study (10 vs 14% of patients; HR 0.67; 95% CI 0.42–1.08; log-rank p = 0.10; median time on study drug 96 and 91 weeks, respectively) [24]”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lyseng-Williamson, K.A., Behr, J. Correction to: Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. Drugs Ther Perspect 35, 47 (2019). https://doi.org/10.1007/s40267-018-0586-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-018-0586-z